CNBC
US · 1 hrs ago
✦ 72◉ Centre
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
72Credibility
0Ratings
0Comments
AI Analysis
Credibility 72/100
Partisan intensity 35/100
ObjectivePartisan
◉ Centre ✓ Fair headline
Biogen is moving an experimental Alzheimer's drug into late-stage trials based on early data showing it may reduce tau protein levels and slow cognitive decline, particularly at lower doses.
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!